Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC
Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...
Cancer
RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC
Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...
Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer
China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...
Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC
China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...
Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...
ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...
InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D
China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...
Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...
Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...